IBA and PET Pharm Bio sign contract to install a Cyclone® IKON in Taiwan
Louvain-La-Neuve, Belgium, May 21, 2025 – IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the world's leading provider of radiopharmaceutical production solutions, announces it has signed a contract with PET Pharm Bio to install a PET and SPECT isotopes production center in Taipei, Taiwan. PET Pharm Bio is a manufacturer and provider of medical isotopes used for oncology diagnosis and therapy.
The radioisotopes production center will be equipped with a Cyclone® IKON and will include beam lines, solid targets for SPECT and PET isotopes, as well as radiochemistry solutions. The new PET Pharm Bio radiopharmacy will also benefit from IBA IntegraLab® design and third parties integration services ensuring the full GMP compliance of this production center.
This new GMP radiopharmacy will be used to produce novel radiopharmaceuticals for applications in theranostics and targeted therapies, including Germanium-68 (used for Germanium-68/Gallium-68 generators), Iodine-123, Thalium-201, Zirconium-89 and Copper-64.
The typical end-user price for a Cyclone® IKON solution is between EUR 10 and 15 million, depending on options and associated equipment.
John Yang, Chairman of PET Pharm Bio Taiwan R.O.C., said: 'With IBA Cyclone® IKON 30 MeV as the backbone, which makes the production of numerous theranostic radiopharmaceuticals possible, PET Pharm Bio will be quickly propelled into a new territory previously not existing in Taiwan and Southeast Asia. As the largest radiopharmaceutical GMP manufacturer in Taiwan, partnering with IBA elevates us to the rank of developers of innovative radiopharmaceuticals targeting not only markets in Taiwan, but globally.'
Charles Kumps, President of IBA RadioPharma Solutions, added: 'We are pleased to partner with PET Pharm Bio and support them in their ambition to produce and deliver key radiopharmaceuticals to advance nuclear medicine applications in the region. There are a growing number of clinical trials and an increase in new radiotherapeutic molecule developments, with many companies recognizing the great potential of theranostics. The acquisition of IBA's Cyclone® IKON solution will enable PET Pharm Bio to leverage a versatile and high-power system at minimal running costs.'
***ENDS***
About PET Pharm Bio Taiwan R.O.C.
Since its establishment in year 2011, PET Pharm Bio has been dedicated to the research, development, and production of radiopharmaceuticals, providing high-quality medical solutions to patients nationwide. We strive to be the best partner for nuclear medicine physicians and patients alike. Our vision is to advance precision diagnosis and treatment in nuclear medicine, improve patient health, and become a leader in the radiopharmaceutical field both in Taiwan and globally. With innovation, quality, and service at our core, we are committed to driving the future of radiopharmaceuticals forward.
About IBA IBA (Ion Beam Applications S.A.) is the world leader in particle accelerator technology. The company is the leading supplier of equipment and services in the fields of proton therapy, considered as the most advanced form of radiation therapy available today, as well as industrial sterilization, radiopharmaceuticals and dosimetry. The company, based in Louvain-la-Neuve, Belgium, employs approximately 2,100 people worldwide. IBA is a certified B Corporation (B Corp) meeting the highest standards of verified social and environmental performance.
IBA is listed on the pan-European stock exchange EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).
More information can be found at: www.iba-worldwide.com
CONTACTS
Olivier LechienCorporate Communication Director+32 10 475 890communication@iba-group.com
ICR HealthcareAmber Fennell, Angela Gray, Chris Welsh+44 (0) 20 3709 5700IBA@icrhealthcare.com
Attachment
250521-Cyclone_IKON-Taiwan-ENb
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
New Balance's 'Comfortable' Fresh Foam Hiking Shoes Are Already $44 Off
The Arena Media Brands, LLC and respective content providers may receive compensation for some links to products and services on this website. New Balance's 'Comfortable' Fresh Foam Hiking Shoes Are Already $44 Off originally appeared on Athlon Sports. Outdoor enthusiasts, take notice. You can score a good deal right now on a pair of New Balance Fresh Foam X Hierro Hiker Shoes, which the athletic retailer describes as "an easy-wearing, waterproof hiker with grippy treads and cushioned midsole for year-round exploration." Normally $190, New Balance is offering this newer model for 23% off, now down to $146. Sizes range from US men's 7 to 16 and US women's 5 to 13, and wide sizes are also available. The available color, pictured below, is "SHIPYARD with DOCKSIDE and Sea Salt." New Balance Reviews: What Are Customers Saying? These hybrid hikers don't have a ton of buyer reviews quite yet, but the early returns are positive, with an overall rating of 4.8 stars out of 5.0. Here is what a few shoppers have said online: "Great Hiking Shoe. Very comfortable, with great support." "They fit good and look good. Have received multiple compliments wanting to know where I got them." "Very comfortable and good for long hikes on uneven terrain." Fresh Foam X Hierro Hiker Shoes, $146 (Was $190) at New Balance More Product and Shipping Details In addition to its "incredible comfort," New Balance's website highlights that the "GORE-TEX® waterproof fabric protects feet from wind, rain and water without sacrificing breathability." These also offer Toe Protect technology, which helps shield your feet from "rocks, roots and debris" as you soak in the trails. Free shipping is offered on these hiking shoes, but be sure to allow up to 2-5 business days once shipped. Store pickup is available at select locations. New Balance's 'Comfortable' Fresh Foam Hiking Shoes Are Already $44 Off first appeared on Athlon Sports on Aug 20, 2025 This story was originally reported by Athlon Sports on Aug 20, 2025, where it first appeared.
Business Wire
3 hours ago
- Business Wire
Sonendo Strengthens Leadership Team With Promotion of John McGaugh to Chief Operating Officer
LAGUNA HILLS, Calif.--(BUSINESS WIRE)--Sonendo, Inc. ('Sonendo' or the 'Company') (OTC Pink: SONX), a leading dental technology company and developer of the GentleWave® System, today announced the promotion of John McGaugh to Chief Operating Officer. Mr. McGaugh previously held the position of Senior Vice President of Operations. 'Since Sonendo embarked on its strategic reset in early-2024, the Company has stabilized revenue, generated significant leverage in gross margin, and meaningfully lowered total operating expenses, adjusted EBITDA loss and cash burn,' stated Bjarne Bergheim, President and Chief Executive Officer of Sonendo. 'John has been a significant contributor to all those improvements, and we expect he will continue to drive additional operating leverage as the Company continues to execute its plans to achieve profitability. John is a valuable member of the team, and I am excited to see him take on the role of Chief Operating Officer.' In addition to his previous responsibilities overseeing quality, manufacturing, supply chain, and technical services operations, Mr. McGaugh now has oversight of Sonendo's capital and consumables sales teams and commercial operations. Mr. McGaugh has over 20 years overseeing global manufacturing operations. He joined Sonendo in May 2023 and has been instrumental in leading significant operational efficiencies with console assembly and procedure instrument margin contributions. Prior to his time at Sonendo, Mr. McGaugh served as a multi-site operational leader for Abbott Vascular. In addition to his experience at Abbott, Mr. McGaugh has held leadership roles at Boston Scientific and American Medical Systems. About Sonendo Sonendo is a commercial-stage medical technology Company focused on saving teeth from tooth decay, the most prevalent chronic disease globally. Sonendo develops and manufactures the GentleWave® System, an innovative technology platform designed to treat tooth decay by cleaning and disinfecting the microscopic spaces within teeth without the need to remove tooth structure. The system utilizes a proprietary mechanism of action, which combines procedure fluid optimization, broad-spectrum acoustic energy and advanced fluid dynamics, to debride and disinfect deep regions of the complex root canal system in a less invasive procedure that preserves tooth structure. The clinical benefits of the GentleWave System when compared to conventional methods of root canal therapy include improved clinical outcomes, such as superior cleaning that is independent of root canal complexity and tooth anatomy, high and rapid rates of healing and minimal to no post-operative pain. In addition, the GentleWave System can improve the workflow and economics of dental practices. For more information about Sonendo and the GentleWave System, please visit To find a GentleWave doctor in your area, please visit Forward Looking Statements This news release includes forward-looking statements (statements which are not historical facts) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, the Company's ability to continue to drive additional operating leverage and/or execute its plans to achieve profitability, whether as a result of Mr. McGaugh or otherwise. You are cautioned that such statements are not guarantees of future performance and that our actual results may differ materially from those set forth in the forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions; speak only as of the date they are made; and, as a result, are subject to risks and uncertainties that may change at any time. Factors that could cause the Company's actual results to differ materially from these forward-looking statements are described in detail in the 'Risk Factors' section of the Company's Annual Report on Form 10-K that was filed with the Securities and Exchange Commission on March 26, 2025. Such filings are available at The Company undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent developments, events, or circumstances, except as may be required under applicable securities laws. Readers are cautioned not to put undue reliance on forward-looking statements, and the Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
Yahoo
3 hours ago
- Yahoo
Onco360 adds Modeyso™ (dordaviprone) to portfolio of Oncology and Rare Cancer therapies as a National Specialty Pharmacy Provider
LOUISVILLE, Ky., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation's leading independent Specialty Pharmacy, has been selected as a pharmacy partner by Jazz Pharmaceuticals for Modeyso™ (dordaviprone). It is indicated for the treatment of adult and pediatric patients one year of age and older with diffuse midline glioma harboring an H3 K27M-mutation with progressive disease following prior therapy.1 This indication was approved based on five open-label, non-randomized clinical trials conducted in the U.S. (ONC006 [NCT02525692], ONC013 [NCT03295396], ONC014 [NCT03416530], ONC016 [NCT05392374], and ONC018 [NCT03134131]).1 'Onco360 is grateful for the opportunity to add Modeyso™ to our expansive portfolio of cancer and rare disease therapies as the first and only FDA-approved treatment for pediatric and adult patients with diffuse midline glioma,' said Benito Fernandez. 'We are proud and humbled to be part of this innovative treatment in support of patients, caregivers and families impacted by this devastating disease.' Dordaviprone is a protease activator of the mitochondrial caseinolytic protease P (ClpP) and inhibits dopamine D2 receptor (DRD2). In vitro, dordaviprone activates the integrated stress response, induces apoptosis, and alters mitochondrial metabolism, leading to restored histone H3 K27 trimethylation in H3 K27M-mutant diffuse glioma.1 The efficacy of Modeyso was evaluated in an integrated efficacy population of 50 adult and pediatric patients with recurrent H3 K27M-mutant diffuse midline glioma enrolled across five open-label, non-randomized clinical trials.1 The primary outcome was overall response rate (ORR) of 22% (95% CI: 12,36). The trial also demonstrated a duration of response of 10.3 months (95% CI: 7.3, 15.2) with 73% maintaining their response for at least six months and 27% for at least 12 months.1 Dordaviprone demonstrated manageable safety and tolerability adverse events. The most common adverse reactions (≥20 %; all causality) experienced with dordaviprone were fatigue, headache, nausea, vomiting, and musculoskeletal pain.1 Please see the full Prescribing Information for Modeyso. About Onco360 Oncology Pharmacy:Onco360 is the nation's largest independent Oncology Pharmacy and clinical support services company. Onco360 was founded in 2003 to bring together the stakeholders involved in the cancer treatment process and serve the specialized needs of oncologists, patients, hospitals, cancer centers of excellence, manufacturers, health plans, and payers. It dispenses nationally through its network of URAC-, and ACHC-accredited Oncology Pharmacies. Onco360 is headquartered in Louisville, Kentucky, and is a flagship specialty pharmacy brand of PharMerica Corporation, a leading institutional pharmacy, specialty infusion, and hospital services company servicing healthcare facilities in the United States. For more information about Onco360, please visit Media Contact: Benito Fernandez, Chief Commercial References:1Modeyso™ (Dordaviprone) [Package Insert]. Palo Alto, CA. Jazz Pharmaceuticals. in to access your portfolio
